Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

AstraZeneca has received approval from the FDA for its BTK inhibitor, Calquence (acalabrutinib), for first-line use in MCL.

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

"AstraZeneca secures first BTK approval in first-line mantle cell lymphoma" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...